… Officer since 2022, following his tenure as Chief Innovation Officer from 2014 to 2022. Gerard has an extensive … and development and is currently in charge of our Innovation unit. Antisense oligonucleotides (AONs) have …
This presentation highlights the therapeutic possibilities of Axiomer platform that are not limited to disease causing mutations and can potentially address high unmet medical needs by editing wild-type RNA to engineer proteins or modify their function as well as creating de novo mutations.
… platform for the exchange and sharing of insights and innovations to drive the future of clinical development in … platform for the exchange and sharing of insights and innovations to drive the future of clinical development in …
Axiomer platform presentation highlighting the potential of Editing Oligonucleotides (EONs) to address liver originated disorders. Presented at the RNA Editing Gordon Research Conference on March 23, 2023 by Gerard Platenburg - ProQR Therapeutics.
ProQR recognizes the importance of advancing diversity, equity, and inclusivity (DEI) in the workplace to inspire each employee to fully thrive and to make their maximum contribution to ProQR.
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
